The Scale of the Market Versus Its Actual Content
The global arena for menopausal health is witnessing unprecedented growth, with the worldwide market currently assessed at nearly $17 billion. Industry analysts project this figure to climb to $25 billion by 2030, driven by a desperate need for interventions targeting hot flushes, sleep disruption, and mood shifts. Yet, a damning report from the consumer watchdog Which? casts a shadow over this expansion. The organisation revealed that a significant portion of the top-selling products lacking meaningful therapeutic value, despite commanding price tags several times higher than basic dietary staples. The contradiction is jarring: billions of pounds are flowing into a sector that is increasingly indistinguishable from a collection of unvalidated claims rather than evidence-based healthcare. This misalignment between price point and scientific merit raises urgent questions about the quality of care offered to those navigating this transformative stage of life.
The Promise and the Price Tag
When examining the specific products currently dominating shelves, the discrepancy becomes undeniable. Retailers ranging from Asda to Boots sell a dizzying array of “women over 45” blends, often marketed as revolutionary solutions to hormonal decay. Consider Asda’s A-Z Multivitamins & Minerals, a formulation costing just six pence a day or roughly £22 annually. This budget-friendly option provides all essential vitamins and includes robust doses of calcium and magnesium—nutrients crucial for bone density maintenance as ovarian function declines. In stark contrast, premium alternatives offer little substance for their price. The most expensive standout on the market, Love Mushrooms’ Empower, costs approximately £485 a year and relies on a cocktail of generic ingredients that fail to target the specific physiological needs of the perimenopausal phase. Even mid-range options like Wild Nutrition’s Women’s 45+ Daily Multi Nutrient, priced at around £468 yearly, suffer from critical deficiencies, delivering minuscule amounts of Vitamin D and calcium that fall well beneath NHS-recommended daily allowances. These disparities highlight a troubling trend where profitability is prioritised over genuine patient benefit.
Expert Alarms and the Quest for Evidence-Based Care
The discrepancies identified by Which? have not gone unnoticed by the medical community
